Navigation Links
Investors Acquire Share in Sangui BioTech GmbH
Date:4/21/2008

WITTEN, Germany, April 21 /PRNewswire-FirstCall/ -- A group of German investors is about to acquire up to 10% of the shares of SanguiBioTech GmbH, Witten, for a purchasing price of up to EUR 750,000. The acquisition will be effectuated by way of a capital increase which will be subscribed to by the investors. It will become effective after the investment sum will have been paid in on a Sangui account and after the capital increase will have been entered in the German register of commercial companies. The majority of those investors are already engaged as shareholders of Sangui BioTech International, Inc., and by subscribing to convertible promissory notes.

Hubertus Schmelz, Managing Director of SanguiBioTech GmbH, said: "We are glad that our investors show uninterrupted confidence in Sangui's future. Their thorough understanding of the long term perspective of our products and projects is highly appreciated. This renewed investment will mainly serve to finance ongoing business as well as special initiatives to promote further development, marketing and sales activities."

SanguiBioTech GmbH is a wholly owned subsidiary of Sangui BioTech International, Inc. (http://www.pinksheets.com: SGBI)

Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other "forward-looking" information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions. Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," and variations of such words and similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

For more information please contact:

Joachim Fleing

Phone: +49-16-07-41-27-17

Fax: +49-23-02-915-191

e-mail: fleing@sangui.de


'/>"/>
SOURCE Sangui BioTech International, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. DuPont Leaders Brief Investors on Agriculture Businesses
2. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
3. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference
4. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Bear Stearns Conference
5. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference
6. XTL Biopharmaceuticals Ltd. Announces $9.6 Million Private Placement to Institutional Investors
7. PURE Bioscience to Present at Biocom Investors Conference
8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Piper Jaffray Conference
9. Advanced Life Sciences Enters Into Definitive Securities Purchase Agreements for $20 Million with New and Existing Institutional Investors
10. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at JPMorgan Conference
11. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/9/2017)... , Oct. 9, 2017  BioTech Holdings ... mechanism by which its ProCell stem cell therapy ... limb ischemia.  The Company, demonstrated that treatment with ... of limbs saved as compared to standard bone ... molecule HGF resulted in reduction of therapeutic effect.  ...
(Date:10/9/2017)... ... October 09, 2017 , ... The Giving Tree ... products targeting the needs of consumers who are incorporating medical marijuana into their ... Phoenix, Arizona. , As operators of two successful Valley dispensaries, The Giving Tree’s ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... its ProxiMeta™ Hi-C metagenome deconvolution product, featuring the first commercially available Hi-C ... software to perform Hi-C metagenome deconvolution using their own facilities, supplementing the ...
(Date:10/6/2017)... ... October 06, 2017 , ... On Tuesday, October 24th, ABC² ... the first-ever adaptive clinical trial for glioblastoma (GBM). The featured speaker will be ... and open to the public, but registration is required. , WHAT: ABC² ...
Breaking Biology Technology:
(Date:5/16/2017)... --  Bridge Patient Portal , an enterprise patient ... Systems , an electronic medical record solutions developer ... a partnership to build an interface between the ... products, including Centricity Practice Solution (CPS), Centricity Business ... integrations will allow healthcare delivery networks using GE ...
(Date:4/24/2017)... WASHINGTON , April 24, 2017 ... counsel and partner with  Identity Strategy Partners, LLP ... "With or without President Trump,s March 6, ... Foreign Terrorist Entry , refugee vetting can be instilled ... refugee resettlement. (Right now, all refugee applications are ...
(Date:4/18/2017)... Inc., a global expert in SoC-based imaging and computing solutions, has ... features the company,s hybrid codec technology. A demonstration utilizing TeraFaces ® ... be showcased during the upcoming Medtec Japan at Tokyo Big Sight ... Las Vegas Convention Center April 24-27. ... Click here for an image of the ...
Breaking Biology News(10 mins):